Nuclear Factor-Kappa B as a Molecular Target in Malignant Pleural Mesothelioma
نویسندگان
چکیده
منابع مشابه
Gli as a Novel Therapeutic Target in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) is a highly aggressive tumor with poor prognosis. Current treatment is rarely curative, thus novel meaningful therapies are urgently needed. Inhibition of Hedgehog (Hh) signaling at the cell membrane level in several cancers has shown anti-cancer activity in recent clinical studies. Evidence of Hh-independent Gli activation suggests Gli as a more potent ther...
متن کاملMolecular Pathogenesis of Malignant Pleural Mesothelioma
Malignant mesothelioma is a rare, highly aggressive cancer which arises from the mesothelial cells which form the lining of the pleural, and less frequently the peritoneal cavities. Malignant pleural mesothelioma (MPM) is an emergent neoplasm, as it was rarely diagnosed prior to the middle of the 20th century. The incidence has risen steadily since 1970, and there are currently an estimated 300...
متن کاملA molecular targeting against nuclear factor-κB, as a chemotherapeutic approach for human malignant mesothelioma
Chronic inflammation due to the absorption of asbestos is an important cause of mesothelioma. Although the increased prevalence of mesothelioma is a serious problem, the development of effective chemotherapeutic agents remains incomplete. As the nuclear factor-κB (NF-κB) pathway contributes to malignant transformation of various types of cells, we explored NF-κB activity in three different path...
متن کامل[Malignant pleural mesothelioma].
Overview Mesothelioma is a rare cancer that is estimated to occur in approximately 2500 people in the United States every year.1,2 These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) focus on malignant pleural mesothelioma (MPM), which is the most common type; mesothelioma can also occur in other sites (e.g., peritoneum, pericardium, tunica vaginalis testis). The disease is di...
متن کاملAberrant nuclear factor-kappa B activity in acute myeloid Leukemia: from molecular pathogenesis to therapeutic target
The overall survival of patients with acute myeloid leukemia (AML) has not been improved significantly over the last decade. Molecularly targeted agents hold promise to change the therapeutic landscape in AML. The nuclear factor kappa B (NF-κB) controls a plethora of biological process through switching on and off its long list of target genes. In AML, constitutive NF-κB has been detected in 40...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2012
ISSN: 0923-7534
DOI: 10.1016/s0923-7534(20)34076-x